News

To combat rising maternal mortality, researchers at Saint Luke's Mid America Heart Institute and UMKC are leading a first of its kind study to create better care for moms with heart conditions during pregnancy.

Alexis Ellington has a renewed outlook on life after being the first Saint Luke's patient to receive a new cancer treatment called Bispecific T-cell Engagers therapy, or BiTE.

A local man with heart failure who was told numerous times he only had months to live gets a second chance at life after treatment at Saint Luke's.

Dr. Adnan Chhatriwalla, interventional cardiologist at Saint Luke’s Mid America Heart Institute, talks about symptoms of heart valve disease, treatment, and keys to long-term heart health.

One patient's experience more than a decade ago was a pivotal moment for both Saint Luke’s Mid America Heart Institute and Saint Luke's Hospital Maternal-Fetal Medicine Program.

The four-year observational study will research U.S. pregnant people with cardiovascular disease to better understand and combat maternal mortality and morbidity.

We are talking about lung cancer and how precision oncology helps patients diagnosed with the disease with treatment.

In the past, many women born with a heart condition were told they would not be able to birth children safely.

Over the years, they have done everything together: graduated high school, tied the knot, bought their first home, and raised a family. For all they have shared, they never dreamed of sharing a cancer diagnosis.